38998-05-9

Basic information

• Product Name: 4,7-dimethoxyindane
• Synonyms: 4,7-dimethoxyindane
• CAS NO: 38998-05-9
• Molecular Weight: 178.231
• Mol File: 38998-05-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4,7-dimethoxyindane(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7-dimethoxyindane(38998-05-9)
• EPA Substance Registry System: 4,7-dimethoxyindane(38998-05-9)

Safety Data

• Hazardous Substances Data: 38998-05-9(Hazardous Substances Data)

Upstream product

• 52428-09-8 4,7-dimethoxyindan-1-one 

Downstream Products

• 1092552-86-7 3-[4-(7-methoxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid ethyl ester 
• 38998-04-8 7-methoxy-indan-4-ol 

Relevant articles and documents

Synthesis and rearrangement of cage [4.3.2]propellanes that contain a spiro linkage

Rearranged cage ketones 6a and 6b are reported in eight linear synthetic steps from 2,5-dimethoxybenzaldehyde 9 without the use of protecting groups. In this regard, Diels–Alder reaction, [2+2]photocycloaddition and Lewis acid promoted rearrangement with BF3·OEt2 were used as key steps. Surprisingly, during the ring expansion process with Lewis acid, solvent in-corporation occurred. This rearrangement approach has provided difficult complex targets through non-obvious synthetic routes. The rearrangement process demonstrated here opens up a new synthetic strategy to interesting and unusual cage molecules.

Novel Compounds

The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

Tetracyano-4,7-indanoquinodimethanes: The first TCNQs with an indan nucleus

8,8,9,9-Tetracyano-4,7-indanoquinodimethane 5-chloro-8,8,9,9-tetracyano-4,7-indanoquinodimethane, the first members of the hitherto unreported family of tetracyanoindanoquinodimethanes, have been synthesized from the corresponding 4,7-indandicarboxylic acids by the method of Yamaguchi. The indan-TCNQs are part of a series of polycyclic TCNQs which include 11,11,12,12-tetracyano-9,10-anthraquinodimethane and 9,9,10,10-tetracyano-1,4-naphthoquinodimethane, that have been prepared in our laboratory. A disadvantage found with the earlier polycyclic TCNQs was the non-coplanarity of their rings and the dicyanomethylene moities: a planar system is essential to efficient electrical conductivity of TCNQs in CT salts. X-ray analysis has shown 8,8,9,9-tetracyano-4,7-indanoquinodimethane to be more planar compared with tetracyanoanthraquinodimethanes and tetracyanonaphthoquinodimethanes. The half-wave potentials of the chlorotetracyanoindanoquinodimethane show it to be a stronger electron acceptor than several known TCNQs and its cyclic voltammogram indicate two single-electron reversible redox processes.